Dr. Brigid S. Boland, M.D.
Gastroenterology (Gastroenterology Physician)
200 W Arbor Dr, Ucsd Medical Center
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 172
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of California, San Francisco School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
CA license A1112520
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 172
- Services billed
- 492
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 149 | 80 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 70 | 68 |
| Biopsy of large bowel using a flexible endoscope | 58 | 56 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 42 | 29 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | 28 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | 17 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Stelara (ustekinumab) | 56 |
| Rinvoq (upadacitinib) | 43 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in San Diego, CA | 36 |
| Mesalamine Other prescribers in San Diego, CA | 34 |
| Humira(Cf) Pen (adalimumab) Other prescribers in San Diego, CA | 32 |
| Omeprazole Other prescribers in San Diego, CA | 29 |
| Budesonide Ec (budesonide) Other prescribers in San Diego, CA | 20 |
| Balsalazide Disodium | 19 |
| Famotidine Other prescribers in San Diego, CA | 17 |
| Azathioprine Other prescribers in San Diego, CA | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $9,059 in total to this clinician.
| Celltrion USA Inc. | $7,566 |
|---|---|
| Genzyme Corporation | $1,098 |
| Janssen Biotech, Inc. | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | $160 |
| AbbVie Inc. | $74.25 |
| Consulting Fee | $8,664 |
|---|---|
| Food and Beverage | $395 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Celltrion USA Inc. May 5, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY | $3,700 |
| Celltrion USA Inc. Nov 4, 2025 | Consulting Fee | $3,700 |
| Genzyme Corporation Dec 31, 2025 | Consulting Fee | $1,098 |
| Celltrion USA Inc. May 5, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY · in-kind | $150 |
| Celltrion USA Inc. May 5, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY · in-kind | $16.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 4 companies. The companies reported $777,544 in research payments for these studies, mostly to the institutions running them.
- NULL
Merck Sharp & Dohme LLC - A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease AMALTHEA
AstraZeneca UK Limited - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP)
AbbVie Inc. - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. · Active, not recruiting · NCT03345823 - A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
E.r. Squibb & Sons, L.l.c. - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie Inc. · Recruiting · NCT06548542 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT03398135 - M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. - M14-327 - A Study to Evaluate the Long-Term Efficacy Safety and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn Disease
AbbVie Inc. - A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
AbbVie Inc. · Completed · NCT02782663
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.